by Jim Shamp, NCBiotech writer — January 7, 2021 .
RESEARCH TRIANGLE PARK – California gene therapy innovator Adverum Biotechnologies announced plans today to invest $83 million to establish a manufacturing site in Durham that will employ 202 people at an average salary of $93,762 when fully operational.
It’s the latest in a string of cell- and gene-therapy companies drawn to the Triangle for its trained workforce, academic prowess and attractive business, social and meteorological climate.
The publicly held company, (Nasdaq: ADVM), is a clinical-stage gene therapy company targeting unmet medical needs in serious ocular and rare diseases. Adverum’s lead product candidate, ADVM-022, is a one-time injection into the eye to treat conditions such as wet age-related macular degeneration and diabetic macular edema.